Ciglitazone

This classification denotes an anti-diabetic agent with the molecular formula C18H23NO3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) U8QXS1WU8G, chemically known as 2,4-thiazolidinedione, 5-((4-((1-methylcyclohexyl)methoxy)phenyl)methyl)-, (+-)- but more generally known as ciglitazone, which bears US NIH Compound Identifier 2750. European Medicines Agency schedules Ciglitazone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06260MIG. The term CIGLITAZONE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 38, No. 6, 1984, List 24). CIGLITAZONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule ciglitazone under HS 29341000 and SITC 51579. As of Q4 2014, CIGLITAZONE remains US FDA's Preferred Term for this commodity. Ciglitazone bears US NLM identifiers UMLS ID C0055721 and NCI Concept Code C72726. SMILES: S1C(CC2CCC(OCC3(CCCCC3)C)CC2)C(=O)NC1=O.